Helene F. Rosenberg, M.D., Ph.D.Building 10, Room 11C21510 Center DriveBethesda, MD 20892-1883Phone: 301-402-1545Fax: firstname.lastname@example.org
Chief, Inflammation Immunobiology Section, LAD
The Inflammation Immunobiology Section aims to explore the link between inflammation and infectious disease, specifically, the unique inflammatory sequelae elicited by respiratory virus pathogens. Our laboratory utilizes molecular, cellular, bioinformatics, and in vivo approaches to elucidate novel pathways and to gain insight into critical interactions.
One primary focus of the laboratory program is the eosinophil, an enigmatic leukocyte whose role in innate immunity remains a subject of controversy. Eosinophils are perhaps best known for their contributions to the functional pathophysiology of allergic asthma; however, evolution tells us that the ability to induce pathology cannot be a raison d’être for any existing cell lineage. As such, several distinct lines of evidence have led Dr. Rosenberg's group to consider the possibility that eosinophils and their unique eosinophil secretory ribonucleases may have unrecognized interactions with asthma-exacerbating factors, most notably respiratory virus pathogens.
In conjunction with the aforementioned studies, Dr. Rosenberg's lab has developed a novel mouse model of respiratory viral infection using the natural rodent pneumovirus pathogen, pneumonia virus of mice (PVM). PVM undergoes robust replication in inbred mouse models, and reproduces many of the clinical and pathologic features of the more severe forms of RSV infection in human infants. With this model, Dr. Rosenberg’s laboratory is conducting studies aimed at elucidating novel inflammatory pathways and original immunomodulatory therapies.
Dr. Rosenberg was awarded both M.D. and Ph.D. degrees from The Rockefeller University and Cornell University Medical College (1984, 1985). Following postdoctoral research at Harvard University, she joined the National Institutes of Health in 1991 and became a section chief in 2002.
From left to right: Kelsey Yamada, Helene Rosenberg, Kim Dyer, Tyler Rice, Caroline Percopo, Kendal Karpe
Percopo CM, Dyer KD, Ochkur SI, Luo JL, Fischer ER, Lee NA, Lee JJ, Domachowske JB, Rosenberg HF. Activated mouse eosinophils protect against lethal respiratory virus infection. Blood. 2013. In press.
Glineur SF, Renshaw RW, Percopo CM, Dyer KD, Dubovi EJ, Domachowske JB, Rosenberg HF. Novel pneumoviruses (PnVs): evolution and inflammatory pathology. Virology. 2013 Sep 1;443(2):257-64.
Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013. Jan;13(1):9-22.
Rosenberg HF, Domachowske JB. Inflammatory responses to respiratory syncytial virus (RSV) infection and the development of immunomodulatory pharmacotherapeutics. Curr Med Chem.2012 Apr 1;19(10):1424-31.
Bennett NJ, Tabarani CM, Bartholoma NM, Wang D, Huang D, Riddell SW, Kiska DL, Hingre R, Rosenberg HF, Domachowske JB. Unrecognized viral respiratory tract infections in premature infants during their birth hospitalization: a prospective surveillance study in two neonatal intensive care units. J Pediatr. 2012 Nov;161(5):814-8.
Gabryszewski SJ, Bachar O, Dyer KD, Percopo CM, Killoran KE, Domachowske JB, Rosenberg HF. Lactobacillus-mediated priming of the respiratory mucosa protects against lethal pneumovirus infection. J Immunol. 2011 Jan 15;186(2):1151-61.
Visit PubMed for a complete publication listing.
back to top
Last Updated November 22, 2013